SCHEMBL4617523

SCHEMBL4617523

COC1(Cl)N=C(Cl)C=CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18901327 0.74
SCHEMBL810770 0.70
SCHEMBL22042466 0.53
SCHEMBL7399402 0.52
SCHEMBL10512160 0.49
SCHEMBL10642120 0.47
SCHEMBL11374389 0.46 MEN1 (0.42)
SCHEMBL6562332 0.43
SCHEMBL11852016 0.41
SCHEMBL21374382 0.35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230345631-A1 PREPREG, METAL-CLAD LAMINATE, AND PRINTED WIRING BOARD JSR CORPORATION (JP) 2023-10-26 US disclosed
CN-116209706-A Prepreg, metal-clad laminate, and printed wiring board JSR株式会社 2023-06-02 CN disclosed
EP-1891019-A2 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS Aventis Pharmaceuticals Inc. (US) 2008-02-27 EP disclosed
WO-2006044732-A2 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2006-04-27 WO disclosed